Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
209 participants
INTERVENTIONAL
2018-10-15
2019-04-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Canadian Real-World Outcomes of Omnipod Initiation in People With T1D
NCT04226378
A Pilot Study to Assess the Safety, PK and PD of Insulin Injected Via MicronJet or Conventional Needle
NCT00602914
Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Type 1 Diabetes
NCT01684956
A Study to Assess the Effect of Smart Insulin Pens on Glycemic Control and Diabetes-related Burdens
NCT05036343
Study to Compare Intraperitoneal Insulin to Subcutaneous Insulin Administration in Type 1 Diabetes Mellitus
NCT00286962
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Enrolled participants will be randomly assigned to one of the following study arms:
* Control group: participating pharmacists will dispense boxes of standard insulin pen needles to the patient participants
* mCPN group: participating pharmacists will dispense boxes of montméd Coloured Pen Needles to the patient participants
Study Sites and Participating Pharmacists All pharmacies in Canada that provide services to individuals with diabetes who use injectable insulin therapy will be eligible to participate in this study. All participating pharmacists who will play an active role in participant enrollment and the follow-up visits will be required to complete a participation consent form and 2 surveys. The first (Pre-study survey) should be completed after they have been fully trained on the study protocol and their study obligations, and before commencement of study enrollment. The second (Post-study survey) should be completed after the last patient has completed the 30-day follow-up visit. (Refer to Section 11 for the Study Flow).
Randomization Process Participating pharmacists will dispense one of the two study pen needles according to a computer-generated list that will be provided to the participating pharmacy upon site activation
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Standard of care arm - using insulin pen needles as previously prescribed
Control
Use of standard of care insulin pen needle
mCPN intervention
Each box of montméd Coloured Pen Needles (mCPN) has the following five features:
i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message "Change color, change site" siteTM" iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened The current research study has accordingly been designed to determine if a "pharmacist-dispensed montméd Coloured Pen Needle (mCPN) intervention" will improve injection site rotation relative to the standard dispensing of non-mCPN insulin pen needles.
mCPN Intervention
Each box of montméd Coloured Pen Needles (mCPN) has the following five features:
i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message "Change color, change site" siteTM" iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mCPN Intervention
Each box of montméd Coloured Pen Needles (mCPN) has the following five features:
i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message "Change color, change site" siteTM" iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened
Control
Use of standard of care insulin pen needle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to read the English text on the boxes of the pen needles
Exclusion Criteria
* Current or previous user of mCPN
* Individuals who are unable to understand or communicate in English
* Pregnant women
* Individuals with serious mental illnesses eg. dementia, schizophrenia disorders, bipolar disorders, major depression, etc.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Montméd
UNKNOWN
Pink Pearls Inc
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lori Berard
Nurse Consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lori Berard
Role: PRINCIPAL_INVESTIGATOR
Pink Pearls Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shoppers Drug Mart 2335
Calgary, Alberta, Canada
Claresholm Pharamcy
Claresholm, Alberta, Canada
Rexall 7236
Edmonton, Alberta, Canada
Shoppers Drug Mart 2401
Okotoks, Alberta, Canada
Kipp Mallery Pharmacy
Kamloops, British Columbia, Canada
Our Own Health Centre
Winnipeg, Manitoba, Canada
Shoppers Drug Mart 535
Winnipeg, Manitoba, Canada
Kennegecasis Drugs
Rothesay, New Brunswick, Canada
Zak's Pharmacy
Milton, Ontario, Canada
Niagara Pharmacy
Niagara Falls, Ontario, Canada
Northgate Pharmacy
Sarnia, Ontario, Canada
Murphy's Cornwall Pharmacy
Cornwall, Prince Edward Island, Canada
Pharmacie Jacques Bourget PJC076
Laval, Quebec, Canada
Pharmacy Jean-Coutu Raffaele Delli Colli & Gino Consolante
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
mCPN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.